雌激素受体在骨肉瘤中的作用研究进展

doi:10.3969/j.issn.1673-8640.2022.04.003

摘要/Abstract

摘要：

雌激素受体（ER）属于核受体超家族成员,其发挥生物学功能的方式主要是通过与雌激素结合,诱导下游靶基因转录,并招募一系列辅助调节因子,共同参与调控基因转录。ER不仅在生理条件下发挥促进性器官成熟、副性征发育以及维持性功能等作用,而且在肿瘤的发生、发展中亦发挥着重要的调节作用,如参与调控肿瘤细胞的生长、耐药、上皮-间质转化（EMT）及转移等。ER在骨肉瘤细胞中呈低水平表达,但发挥重要的调节作用,其表达水平或活性可有效改变雌激素/ER依赖的转录因子的表达,影响肿瘤的侵袭、转移、药物敏感性及生长特性等。文章主要就近年来ER在骨肉瘤发生、发展及治疗中的作用进行综述,以期为寻找骨肉瘤治疗的新方案提供思路。

关键词: 雌激素受体, 骨肉瘤, 转移, 耐药, 上皮-间质转化

Abstract:

Estrogen receptor（ER） belongs to the nuclear receptor superfamily,which mainly binds with the ligand estrogen to activate transcription of its target genes. The interaction of ER with estrogen could actively recruit co-regulator factors to influence transcription of ER-dependent genes. ER not only plays a role in promoting sexual organ maturation,parasexual development and maintaining sexual function,but also participates in the regulation of tumor cell growth,drug resistance,epithelial-mesenchymal transformation（EMT） and metastasis during the occurrence and development of tumors. ER is expressed at a low level in osteosarcoma. Regulating the expression level or activity of ER can effectively change the expression of estrogen/ER-dependent transcription factors and affect the invasion,metastasis,drug sensitivity and growth characteristics of tumors. This review focuses on the research progress of ER in the occurrence,development and treatment of osteosarcoma in the recent years,trying to provide new insights for clinic.

Key words: Estrogen receptor, Osteosarcoma, Metastasis, Drug resistance, Epithelial-mesenchymal transformation

中图分类号:

R446.62

孙小丹, 刘鷖雯, 何怡青, 杜艳, 张国良, 高锋, 杨翠霞. 雌激素受体在骨肉瘤中的作用研究进展[J]. 检验医学, 2022, 37(4): 313-318.

SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma[J]. Laboratory Medicine, 2022, 37(4): 313-318.

图/表 3

参考文献 51

[1]	SMELAND S, BIELACK S S, WHE LAN J, et al. Survival and prognosis with osteosarcoma:outcomes in more than 2 000 patients in the EURAMOS-1(European and American Osteosarcoma Study) cohort[J]. Eur J Cancer, 2019, 109:36-50. DOI URL
[2]	ISAKOFF M S, BIELACK S S, MELTZER P, et al. Osteosarcoma:current treatment and a collaborative pathway to success[J]. J Clin Oncol, 2015, 33(27):3029-3035. DOI URL
[3]	SMRKE A, ANDERSON P M, GULIA A, et al. Future directions in the treatment of osteosarcoma[J]. Cells, 2021, 10(1):172. DOI URL
[4]	EATON B R, SCHWARZ R, VATNER R, et al. Osteosarcoma[J]. Pediatr Blood Cancer, 2021, 68(Suppl 2):e28352.
[5]	DAVIS L E, BOLEJACK V, RYAN C W, et al. Randomized double-blind phase Ⅱ study of regorafenib in patients with metastatic osteosarcoma[J]. J Clin Oncol, 2019, 37(16):1424-1431. DOI URL
[6]	ALEXANDER J H, BINITIE O T, LETSON G D, et al. Osteosarcoma:an evolving understanding of a complex disease[J]. J Am Acad Orthop Surg, 2021, 29(20):e993-e1004. DOI URL
[7]	BIELACK S S, KEMPF-BIELACK B, DELLING G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk:an analysis of 1 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3):776-790. DOI URL
[8]	CERSOSIMO F, LONARDI S, BERNARDINI G, et al. Tumor-associated macrophages in osteosarcoma:from mechanisms to therapy[J]. Int J Mol Sci, 2020, 21(15):5207. DOI URL
[9]	ROBERTS R D. Is estrogen the answer for osteosarcoma?[J]. Cancer Res, 2019, 79(6):1034-1035. DOI URL
[10]	LILLO OSUNA M A, GARCIA-LOPEZ J, EL AYACHI I, et al. Activation of estrogen receptor alpha by decitabine inhibits osteosarcoma growth and metastasis[J]. Cancer Res, 2019, 79(6):1054-1068. DOI URL
[11]	FUENTES N, SILVEYRA P. Estrogen receptor signaling mechanisms[J]. Adv Protein Chem Struct Biol, 2019, 116:135-170.
[12]	HANKER A B, SUDHAN D R, ARTEAGA C L. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020, 37(4):496-513. DOI URL
[13]	ZHA Z, SU A, HUO S. Activation of GPER suppresses the malignancy of osteosarcoma cells via down regulation of IL-6 and IL-8[J]. Arch Biochem Biophys, 2018, 660:149-155. DOI URL
[14]	HEWITT S C, KORACH K S. Estrogen receptors:new directions in the new millennium[J]. Endocr Rev, 2018, 39(5):664-675. DOI URL
[15]	WANG Z, CHEN X, ZHAO Y, et al. G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of snail[J]. J Cancer Res Clin Oncol, 2019, 145(1):87-96. DOI URL
[16]	YE Y, XIAO Y, WANG W, et al. ERalpha signaling through slug regulates E-cadherin and EMT[J]. Oncogene, 2010, 29(10):1451-1462. DOI URL
[17]	RENOIR J M, MARSAUD V, LAZENNEC G. Estrogen receptor signaling as a target for novel breast cancer therapeutics[J]. Biochem Pharmacol, 2013, 85(4):449-465. DOI URL
[18]	MONROE D G, SECRETO F J, SUBRAMANIAM M, et al. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells[J]. Mol Endocrinol, 2005, 19(6):1555-1568. DOI URL
[19]	WU C, CHEN R, XU L, et al. Relationship between the expression of oestrogen receptor and progesterone receptor and 18F-FDG uptake in endometrial cancer[J]. Aging(Albany NY), 2020, 12(13):12921-12929.
[20]	DEN BOON J A, PYEON D, WANG S S, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer:role of stromal estrogen receptor signaling[J]. Proc Natl Acad Sci U S A, 2015, 112(25):e3255-e3264.
[21]	ROY P, GEORGE J, SRIVASTAVA S, et al. Inhibitory effects of tea polyphenols by targeting cyclooxygenase-2 through regulation of nuclear factor kappa B,Akt and p53 in rat mammary tumors[J]. Invest New Drugs, 2011, 29(2):225-231. DOI URL
[22]	SOBRINO A, VALLEJO S, NOVELLA S, et al. Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation[J]. Biochem Pharmacol, 2017, 129:67-72. DOI URL
[23]	MANSOURI S, FARAHMAND L, HOSSEINZADE A, et al. Estrogen can restore tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance[J]. Biomed Pharmacother, 2017, 93:1320-1325. DOI URL
[24]	SINGH R R, KUMAR R. Steroid hormone receptor signaling in tumorigenesis[J]. J Cell Biochem, 2005, 96(3):490-505. DOI URL
[25]	WANG C, BAI F, ZHANG L H, et al. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression[J]. Breast Cancer Res, 2018, 20(1):74. DOI URL
[26]	YANG M, LIU B, JIN L, et al. Estrogen receptor β exhibited anti-tumor effects on osteosarcoma cells by regulating integrin,IAP,NF-kB/BCL-2 and PI3K/Akt signal pathway[J]. J Bone Oncol, 2017, 9:15-20. DOI URL
[27]	YANG L, HE J, WEN Y, et al. Nanoscale photodynamic agents for colorectal cancer treatment:a review[J]. J Biomed Nanotechnol, 2016, 12(7):1348-1373. DOI URL
[28]	ZHANG Y, YIN C, ZHOU X, et al. Silencing of estrogen receptor β promotes the invasion and migration of osteosarcoma cells through activating Wnt signaling pathway[J]. Onco Targets Ther, 2019, 12:6779-6788. DOI URL
[29]	DE FRANCESCO E M, MAGGIOLINI M, MUSTI A M. Crosstalk between Notch,HIF-1α and GPER in breast cancer EMT[J]. Int J Mol Sci, 2018, 19(7):2011. DOI URL
[30]	HERNÁNDEZ-SILVA C D, VILLEGAS-PINEDA J C, PEREIRA-SUÁREZ A L. Expression and role of the G protein-coupled estrogen receptor(GPR30/GPER) in the development and immune response in female reproductive cancers[J]. Front Endocrinol(Lausanne), 2020, 11:544.
[31]	ROUHIMOGHADAM M, LU A S, SALEM A K, et al. Therapeutic perspectives on the modulation of G-protein coupled estrogen receptor,GPER,function[J]. Front Endocrinol(Lausanne), 2020, 11:591217.
[32]	PUPO M, PISANO A, LAPPANO R, et al. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts[J]. Environ Health Perspect, 2012, 120(8):1177-1782. DOI URL
[33]	ISHII T, WARABI E. Mechanism of rapid nuclear factor-E2-related factor 2(Nrf2) activation via membrane-associated estrogen receptors:roles of NADPH oxidase 1,neutral sphingomyelinase 2 and epidermal growth factor receptor(EGFR)[J]. Antioxidants(Basel), 2019, 8(3):69.
[34]	KANDA N, WATANABE S. 17Beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression[J]. J Invest Dermatol, 2003, 121(6):1500-1509. DOI URL
[35]	YANG Z M, YANG M F, YU W, et al. Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors:implication for treating osteosarcoma[J]. J Int Med Res, 2019, 47(10):4644-4655. DOI URL
[36]	HALL J M, MCDONNELL D P. The estrogen receptor beta-isoform(ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens[J]. Endocrinology, 1999, 140(12):5566-5578. DOI URL
[37]	PARUTHIYIL S, PARMAR H, KEREKATTE V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest[J]. Cancer Res, 2004, 64(1):423-428. DOI URL
[38]	李洁. 植物雌激素大豆苷元对人骨肉瘤MG63细胞凋亡、分化和生物学性状的影响[D]. 郑州: 郑州大学, 2014.
[39]	YANG Z, YU W, LIU B, et al. Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway[J]. J Orthop Surg Res, 2020, 15(1):50. DOI URL
[40]	牛晓辉, 蔡槱伯, 张清, 等. ⅡB期肢体骨肉瘤189例综合治疗临床分析[J]. 中华外科杂志, 2005, 55(24):1576-1579.
[41]	WANG L, JIANG Z, SUI M, et al. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens:a case control study[J]. BMC Cancer, 2009, 9:226. DOI URL
[42]	HOUTMAN R, DE LEEUW R, RONDAIJ M, et al. Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array,with potential application in predicting responses to tamoxifen[J]. Mol Cancer Ther, 2012, 11(4):805-816. DOI URL
[43]	SUZUKI T, NISHIO K, TANABE S. The MRP family and anticancer drug metabolism[J]. Curr Drug Metab, 2001, 2(4):367-377. DOI URL
[44]	DUAN L, PEREZ R E, HANSEN M, et al. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1[J]. Cancer Biol Ther, 2014, 15(12):1600-1612. DOI URL
[45]	BROZOVIC A, FRITZ G, CHRISTMANN M, et al. Long-term activation of SAPK/JNK,p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance[J]. Int J Cancer, 2004, 112(6):974-985. DOI URL
[46]	GO R E, KIM C W, LEE S M, et al. Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models[J]. Food Chem Toxicol, 2021, 149:112000.
[47]	ALFAKEEH A, BREZDEN-MASLEY C. Overcoming endocrine resistance in hormone receptor-positive breast cancer[J]. Curr Oncol, 2018, 25(Suppl 1):S18-S27.
[48]	WONG K Y, ZHOU L, YU W, et al. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues[J]. J Ethnopharmacol, 2021, 275:114096.
[49]	CRAIG JORDAN V, MCDANIEL R, AGBOKE F, et al. The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators[J]. Steroids, 2014, 90:3-12. DOI URL
[50]	ZHOU L P, WONG K Y, YEUNG H T, et al. Bone protective effects of Danggui Buxue Tang alone and in combination with tamoxifen or raloxifene in vivo and in vitro[J]. Front Pharmacol, 2018, 9:779. DOI URL
[51]	WANG J Y, CHEN C M, CHEN C F, et al. Suppression of estrogen receptor alpha inhibits cell proliferation,differentiation and enhances the chemosensitivity of P53-positive U2OS osteosarcoma cell[J]. Int J Mol Sci, 2021, 22(20):11238. DOI URL

项目	机制	功能	参考文献
ERα	通过碱性磷酸酶降低波形蛋白、MMP9的蛋白表达水平	抑制转移	^[10]
	通过碱性磷酸酶抑制SOX2、OCT4、NANOG基因表达	减弱细胞干性	^[10]
ERβ	激活Wnt信号通路,降低MMP7、MMP9的表达水平	诱导凋亡	^[28]
	激活NF-κB/BCL-2使自噬标志物LC3-Ⅱ表达增加	诱导自噬	^[35]
	抑制PI3K/Akt	诱导凋亡	^[39]
GPER	介导snail的翻译后调控	抑制转移	^[15]
	通过MAPK信号通路降低IL-6 mRNA的稳定性	抑制侵袭转移	^[13]

项目	机制	功能	参考文献
ERα	通过碱性磷酸酶降低波形蛋白、MMP9的蛋白表达水平	抑制转移	^[10]
	通过碱性磷酸酶抑制SOX2、OCT4、NANOG基因表达	减弱细胞干性	^[10]
ERβ	激活Wnt信号通路,降低MMP7、MMP9的表达水平	诱导凋亡	^[28]
	激活NF-κB/BCL-2使自噬标志物LC3-Ⅱ表达增加	诱导自噬	^[35]
	抑制PI3K/Akt	诱导凋亡	^[39]
GPER	介导snail的翻译后调控	抑制转移	^[15]
	通过MAPK信号通路降低IL-6 mRNA的稳定性	抑制侵袭转移	^[13]